RT Journal Article
SR Electronic
T1 SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.27.21256207
DO 10.1101/2021.04.27.21256207
A1 Eric D. Laing
A1 Nusrat J. Epsi
A1 Stephanie A. Richard
A1 Emily C. Samuels
A1 Wei Wang
A1 Russell Vassell
A1 Daniel F. Ewing
A1 Rachel Herrup
A1 Spencer L. Sterling
A1 David A Lindholm
A1 Eugene V. Millar
A1 Ryan C. Maves
A1 Derek T. Larson
A1 Rhonda E. Colombo
A1 Sharon Chi
A1 Cristian Madar
A1 Tahaniyat Lalani
A1 Anuradha Ganesan
A1 Anthony Fries
A1 Christopher J. Colombo
A1 Katrin Mende
A1 Mark P. Simons
A1 Kevin L. Schully
A1 Carol D. Weiss
A1 David R. Tribble
A1 Brian K. Agan
A1 Simon D. Pollett
A1 Christopher C. Broder
A1 Timothy H. Burgess
A1 for the EPICC Study team
YR 2021
UL http://medrxiv.org/content/early/2021/05/02/2021.04.27.21256207.abstract
AB Importance The persistence of SARS-CoV-2 antibodies may be a predictive correlate of protection for both natural infections and vaccinations. Identifying predictors of robust antibody responses is important to evaluate the risk of re-infection / vaccine failure and may be translatable to vaccine effectiveness.Objective To 1) determine the durability of anti-SARS-CoV-2 IgG and neutralizing antibodies in subjects who experienced mild and moderate to severe COVID-19, and 2) to evaluate the correlation of age and IgG responses to both endemic human seasonal coronaviruses (HCoVs) and SARS-CoV-2 according to infection outcome.Design Longitudinal serum samples were collected from PCR-confirmed SARS-CoV-2 positive participants (U.S. active duty service members, dependents and military retirees, including a range of ages and demographics) who sought medical treatment at seven U.S. military hospitals from March 2020 to March 2021 and enrolled in a prospective observational cohort study.Results We observed SARS-CoV-2 seropositivity in 100% of inpatients followed for six months (58/58) to one year (8/8), while we observed seroreversion in 5% (9/192) of outpatients six to ten months after symptom onset, and 18% (2/11) of outpatients followed for one year. Both outpatient and inpatient anti-SARS-CoV-2 binding-IgG responses had a half-life (T1/2) of >1000 days post-symptom onset. The magnitude of neutralizing antibodies (geometric mean titer, inpatients: 378 [246-580, 95% CI] versus outpatients: 83 [59-116, 95% CI]) and durability (inpatients: 65 [43-98, 95% CI] versus outpatients: 33 [26-40, 95% CI]) were associated with COVID-19 severity. Older age was a positive correlate with both higher IgG binding and neutralizing antibody levels when controlling for COVID-19 hospitalization status. We found no significant relationships between HCoV antibody responses and COVID-19 clinical outcomes, or the development of SARS-CoV-2 neutralizing antibodies.Conclusions and Relevance This study demonstrates that humoral responses to SARS-CoV-2 infection are robust on longer time-scales, including those arising from milder infections.However, the magnitude and durability of the antibody response after natural infection was lower and more variable in younger participants who did not require hospitalization for COVID-19. These findings support vaccination against SARS-CoV-2 in all suitable populations including those individuals that have recovered from natural infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded by the Defense Health Program, U.S. DoD, under awards HU0001190002 and HU00012020067, and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under award HU00011920111 and Inter-Agency Agreement Y1-AI-5072.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The referenced human subjects protocol (IDCRP-085) was approved by the Uniformed Services University Institutional Review Board and participating sites. All subjects or their legally authorized representative provide written or verbal informed consent using approved documents and procedures; the consent forms include clauses allowing use of specimens for investigations including those conducted in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.